{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:46:01Z","timestamp":1791931561656,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04967-w","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T05:11:14Z","timestamp":1791781874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research and development of a multi-target HER2 inhibitor (CPD 1) and its mechanism and application in combating HER2-positive breast cancer"],"prefix":"10.1007","volume":"96","author":[{"given":"Jianchao","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"4967_CR1","doi-asserted-by":"crossref","unstructured":"Gong C, Lin Q, Cen Y, Fang X, Shi Y, Chen L, Luo Q, Duan Z (2022) Differences in tumor microenvironment between HER2-positive and HER2-negative breast cancer. J Clin Oncol, 40, e12562\u2013e12562","DOI":"10.1200\/JCO.2022.40.16_suppl.e12562"},{"key":"4967_CR2","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","volume":"24","author":"M Stanowicka-Grada","year":"2023","unstructured":"Stanowicka-Grada M, Senkus E (2023) Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer. Curr Treat Options Oncol 24:1633\u20131650","journal-title":"Curr Treat Options Oncol"},{"key":"4967_CR3","doi-asserted-by":"publisher","first-page":"155550","DOI":"10.1016\/j.prp.2024.155550","volume":"262","author":"S Ahuja","year":"2024","unstructured":"Ahuja S, Khan AA, Zaheer S (2024) Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2. Pathol - Res Pract 262:155550","journal-title":"Pathol - Res Pract"},{"key":"4967_CR4","doi-asserted-by":"crossref","unstructured":"Ferraro E, Nassif RB, Reiner A, Tosi U, Panageas K, Dang CT, Seidman AD, Moss N (2023) SDPS-46 central nervous system (CNS)-related mortality in patients with HER2-positive metastatic breast cancer. NeurO-Oncology Adv, 5(Suppl 3), iii25\u2013iii26","DOI":"10.1093\/noajnl\/vdad070.100"},{"key":"4967_CR5","first-page":"167","volume":"27","author":"L Santos","year":"2025","unstructured":"Santos L, Tomatis F, Ferreira HRS, Almeida SFF, Ciputra E, Sereno J, Almeida R, Teixeira P, Ribeiro AS, Moreira JN, Silva AP, Ferreira L, Abrunhosa AJ, Gomes CM (2025) ENPP1 induces blood-brain barrier dysfunction and promotes brain metastasis formation in human epidermal growth factor receptor 2-positive breast cancer. Neurooncology 27:167\u2013183","journal-title":"Neurooncology"},{"key":"4967_CR6","doi-asserted-by":"publisher","first-page":"177076","DOI":"10.1016\/j.ejphar.2024.177076","volume":"985","author":"G Guglielmi","year":"2024","unstructured":"Guglielmi G, Zamagni C, Del Re M, Danesi R, Fogli S (2024) Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments. Eur J Pharmacol 985:177076","journal-title":"Eur J Pharmacol"},{"key":"4967_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cncr.24735","volume":"116","author":"K Yonemori","year":"2010","unstructured":"Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2\/neu-positive breast cancer. Cancer 116:302\u2013308","journal-title":"Cancer"},{"key":"4967_CR8","doi-asserted-by":"crossref","unstructured":"Angeli E, Paris J, Le Tilly O, Desvignes C, Gapihan G, Boquet D, Pamoukdjian F, Hamdan D, Rigal M, Poirier F, Lutomski D, Azibani F, Mebazaa A, Herbet A, Mabondzo A, Falgarone G, Janin A, Paintaud G, Bousquet G (2024) A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases, vol 13. Experimental Hematology & Oncology, p 41","DOI":"10.1186\/s40164-024-00513-7"},{"key":"4967_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.clbc.2025.06.004","volume":"25","author":"E Shagisultanova","year":"2025","unstructured":"Shagisultanova E, Parris H, Liu L, Giangiuli S, Gao D, Diamond JR, Acharya-Leon R, Kabos P, Borges VF (2025) Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clin Breast Cancer 25:643\u2013649e641","journal-title":"Clin Breast Cancer"},{"key":"4967_CR10","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1535-7163.MCT-15-0923","volume":"15","author":"J Chen","year":"2016","unstructured":"Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L (2016) Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. Mol Cancer Ther 15:2835\u20132844","journal-title":"Mol Cancer Ther"},{"key":"4967_CR11","doi-asserted-by":"publisher","first-page":"32978","DOI":"10.1039\/D4RA06394E","volume":"14","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi LH, El-Sheref EM, Tawfeek HN, Abou-Zied HA, Rabea SM, Br\u00e4se S, Youssif BGM (2024) Design, synthesis, and biological evaluation of novel quinoline-based EGFR\/HER-2 dual-target inhibitors as potential anti-tumor agents. RSC Adv 14:32978\u201332991","journal-title":"RSC Adv"},{"key":"4967_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00044-022-02934-7","volume":"31","author":"PS Dhiwar","year":"2022","unstructured":"Dhiwar PS, Matada GSP, Raghavendra NM, Ghara A, Singh E, Abbas N, Andhale GS, Shenoy GP, Sasmal P (2022) Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. Med Chem Res 31:1401\u20131413","journal-title":"Med Chem Res"},{"key":"4967_CR13","doi-asserted-by":"crossref","unstructured":"Meedendorp D, ter Elst A, \u2019t Hart NA, Groen HJM, Schuuring E, van der Wekken AJ (2018) Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. Front Oncol, 8:176","DOI":"10.3389\/fonc.2018.00176"},{"key":"4967_CR14","doi-asserted-by":"publisher","first-page":"107653","DOI":"10.1016\/j.bioorg.2024.107653","volume":"151","author":"H-N Liu","year":"2024","unstructured":"Liu H-N, Zhu Y, Chi Y, Zhang Y, Li X, Wen W, Shan L-S, Wang Y-T, Dai B (2024) Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy. Bioorg Chem 151:107653","journal-title":"Bioorg Chem"},{"key":"4967_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejca.2021.06.026","volume":"154","author":"F Le Du","year":"2021","unstructured":"Le Du F, Di\u00e9ras V, Curigliano G (2021) The role of tyrosine kinase inhibitors in the treatment of HER2 + metastatic breast cancer. Eur J Cancer 154:175\u2013189","journal-title":"Eur J Cancer"},{"key":"4967_CR16","doi-asserted-by":"publisher","first-page":"114775","DOI":"10.1016\/j.ejmech.2022.114775","volume":"244","author":"M Hu","year":"2022","unstructured":"Hu M, Li Y, Li J, Zhou H, Liu C, liu Z, Gong Y, Ying B, Xie Y (2022) Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. Eur J Med Chem 244:114775","journal-title":"Eur J Med Chem"},{"key":"4967_CR17","doi-asserted-by":"crossref","unstructured":"Feng Y, Gonz\u00e1lez I, Zhang D (2025) 1426 Tucatinib (HER2 Tyrosine Kinase Inhibitor)-Induced Liver Injury.Lab Invest 105(3):103665","DOI":"10.1016\/j.labinv.2024.103665"},{"key":"4967_CR18","doi-asserted-by":"crossref","unstructured":"Singh DD, Lee H-J, Yadav DK (2022) Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Front Pharmacol 13:1089066","DOI":"10.3389\/fphar.2022.1089066"},{"key":"4967_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","volume":"36","author":"Q Wu","year":"2022","unstructured":"Wu Q, Bai B, Tian C, Li D, Yu H, Song B, Li B, Chu X (2022) The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. Cardiovasc Drugs Ther 36:511\u2013524","journal-title":"Cardiovasc Drugs Ther"},{"key":"4967_CR20","doi-asserted-by":"publisher","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","volume":"165","author":"R Roskoski","year":"2021","unstructured":"Roskoski R (2021) Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol Res 165:105463","journal-title":"Pharmacol Res"},{"key":"4967_CR21","doi-asserted-by":"publisher","first-page":"174461","DOI":"10.1016\/j.ejphar.2021.174461","volume":"914","author":"C Peng","year":"2022","unstructured":"Peng C, Fu X, Wang K, Chen L, Luo B, Huang N, Luo Y, Chen W (2022) Dauricine alleviated secondary brain injury after intracerebral hemorrhage by upregulating GPX4 expression and inhibiting ferroptosis of nerve cells. Eur J Pharmacol 914:174461","journal-title":"Eur J Pharmacol"},{"key":"4967_CR22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1080\/15548627.2023.2165323","volume":"19","author":"Q Xue","year":"2023","unstructured":"Xue Q, Yan D, Chen X, Li X, Kang R, Klionsky DJ, Kroemer G, Chen X, Tang D, Liu J (2023) Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy 19:1982\u20131996","journal-title":"Autophagy"},{"key":"4967_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41401-024-01277-w","volume":"45","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wu M-f, Xie M-m, Lu Y, Li C, Xie S-s, Ma W-x, Ji M-l, Hou R, Dong Z-h, He R-b, Zhang M-m, Lu H, Gao L, Wen J-g, Jin J (2024) X.-w. Dong, J.-x. Che and X.-m. Meng, Cpd-A1 alleviates acute kidney injury by inhibiting ferroptosis. Acta Pharmacol Sin 45:1673\u20131685","journal-title":"Acta Pharmacol Sin"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04967-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04967-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04967-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:03:06Z","timestamp":1791928986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04967-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4967"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04967-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}